Kaplan-Meier plots of significant correlations between overall survival (OS) and elevated (>median) Cx30 (a–c), Cx43 (d–f) and Cx46 (g–i) mRNA expression in 1988 breast cancers based on <i>in silico</i> analysis of Illumina array data.

<p>Elevated Cx30 levels were linked with reduced OS in patients with luminal B tumors (a) and in ER positive endocrine therapy treated patients (b), but with a strong tendency for improved OS in ER negative cases (c). Cx43 expression was associated with better OS in the whole cohort (d) and in ER positive endocrine treated patients (e) but showed a strong trend for reduced OS in ER negative patients (f). Cx46 expression was associated with improved OS in the whole cohort (g), in ER negative patients (h) and in HER2 positive patients (i). Significance (at p<0.05) was calculated using the log-rank test. HR: hazard ratio (at 95% Confidence Interval).